Related Experiment Video
Updated: Aug 11, 2026
04:53
An In Vitro Approach to Photodynamic Therapy
Published on: August 17, 2018
[Photodynamic therapy in choroidal new vessels]
1Clinique Ophtalmologique Universitaire, 40, avenue de Verdun, 94010 Créteil, France.
Journal Francais D'Ophtalmologie
|May 15, 2001
Summary
Photodynamic therapy (PDT) using Verteporfin shows promise for treating choroidal new vessels (CNV) in age-related macular degeneration (ARM). While effective in preserving visual acuity, repeated treatments may be necessary due to CNV reperfusion.
Area of Science:
- Ophthalmology
- Photomedicine
Context:
- Age-related macular degeneration (ARM) and myopia can cause choroidal new vessels (CNV).
- Photodynamic therapy (PDT) is an emerging treatment for subfoveal CNV.
Purpose:
- To evaluate the efficacy and safety of Verteporfin-mediated PDT for subfoveal CNV in ARM.
Summary:
- PDT involves intravenous Verteporfin (photosensitizer) followed by 692nm light activation.
- Phase III trials demonstrated Verteporfin PDT preserved visual acuity in 67% of ARM eyes versus 39% in placebo at one year.
- CNV photo-occlusion occurred at 14 days, with partial reperfusion or reproliferation by 3 months, indicating a need for retreatment.
Impact:
- Verteporfin PDT is an effective treatment option for subfoveal CNV, preserving visual function in ARM patients.
- Understanding the treatment dynamics, including reperfusion, is crucial for optimizing PDT protocols and patient management.
